标题：重组人血管内皮抑制素联合调强放疗治疗局部晚期低危鼻咽癌随机对照研究

      作者：张伟 1，戴群 2    (1.阜阳市人民医院放疗科，安徽 阜阳 236003；2.阜阳市肿瘤医院放疗科，安徽 阜阳 236000)

      卷次： 2016年27卷23期

      【摘要】 目的 比较重组人血管内皮抑制素(Endostar)联合调强放疗(IMRT)与 IMRT联合化疗治疗局部晚期低危鼻咽癌(LANC)的临床疗效及安全性。方法 选取阜阳市人民医院放疗科 2011年 1月至 2016年 1月收治的LANC患者80例为研究对象，采用随机数字表法随机分为对照组(n=42)和观察组(n=38)。观察组采用 IMRT放疗联合Endostar，对照组采用 IMRT联合顺铂(DDP)化疗者，两组放疗疗程为6周。放疗结束后3个月进行近期疗效及不良反应评价；同时观察比较两组患者的远期生存率。结果 疗程结束3个月时，观察组和对照组客观缓解率分别为89.5% (34/38)和90.5% (38/42)，差异无统计学意义(P>0.05)；观察组Ⅲ~Ⅳ级黏膜炎、恶心呕吐和白细胞减低发生率分别为23.7% (9/38)、2.6% (1/38)和2.6% (1/38)，均明显低于对照组的42.9% (18/42)、23.8% (10/42)和21.4% (9/42)，差异均有统计学意义(P<0.05)；观察组患者的中位生存时间为55.6个月，对照组为57.1个月，两组患者中位生存时间差异无统计学意义(HR=1.09, 95%CI：0.49~2.38，P>0.05)。结论 Endostar联合 IMRT治疗 LANC的临床疗效与IMRT联合化疗相当，但不良反应明显降低。
      【关键词】 局部晚期鼻咽癌；调强放疗；重组人血管内皮抑制素；临床疗效；不良反应
      【中图分类号】 R739.63 【文献标识码】 A 【文章编号】 1003—6350（2016）23—3854—03

Prospective randomized controlled trials for Endostar combined with intensity-modulated radiation therapy inthe treatment of low-risk locally advanced nasopharyngeal carcinoma.
ZHANG Wei 1, DAI Qun 2. 1. Department ofRadiology, Fuyang People's Hospital, Fuyang 236003, Anhui, CHINA; 2. Department of Radiology, Fuyang CancerHospital, Fuyang 236000, Anhui, CHINA
【Abstract】 Objective To investigate the efficacy and safety of Endostar combined with intensity-modulated ra-diation therapy (IMRT) in the treatment of low-risk locally advanced nasopharyngeal carcinoma (LANC), comparedwith IMRT combined with chemotherapy. Methods Eighty patients with low-risk LANC were retrospectively includedin Fuyang People's Hospital from Jan. 2011 to Jan. 2016. The included 80 cases were randomly divided into observationgroup (n=38) and control group (n=42) according to random number table. Patients in observation group received Endo-star combined IMRT treatment, and patients in control group received DDP chemotherapy combined with IMRT. Thetreatment course was 6 weeks. Three months after radiation, the clinical efficacy and safety were compared between thetwo groups. The patients were followed up to compare the long-term survival. Results Three months after treatment,the objective response rate were 89.5% (34/38) and 90.5% (38/42) for the observation and control group respectively,·论 著·doi:10.3969/j.issn.1003-6350.2016.23.022基金项目：安徽省阜阳市卫生局医学科学研究基金(编号：2012FYKZ008)